ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-10	$0.000001	0.00%	370
26-07-08	$0.000001	-99.00%	1,750

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 10:12:47 2026-07-10 am EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		-99.00%	-99.00%

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.6M 3.33M 3.07M 5.8M 393M 5.91M 39.71M 15.57M 193M 15.4M 15.06M 666M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.14M -1.05M -969K -1.83M -124M -1.87M -12.55M -4.92M -60.91M -4.87M -4.76M -210M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
23-04-11	Insider Buy: Obseva	MT
23-04-05	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
23-03-31	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
23-03-22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
23-03-15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
23-03-13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
23-03-13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
23-03-13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
23-03-13	ObsEva SA Announces Executive Changes	CI
23-03-03	Top Premarket Gainers	MT

22-08-30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
22-08-01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
22-07-29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
22-06-03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
22-04-26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-03-31	ObsEva Files Year End 2022 Financial Statements	GL
23-03-22	OBSEVA SA : Other Events (form 8-K)	AQ
23-03-15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

23-04-20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
23-04-06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
23-04-06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
23-03-31	Obseva bleibt 2022 tief in den roten Zahlen
23-03-31	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.58
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-04-05	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-27	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23-02-22	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	0.00%	-99.00%	-	-	117
WUXI APPTEC CO., LTD.	-2.48%	-2.22%	+55.85%	+79.12%	54.88B
ARGENX SE	-0.55%	-6.57%	+58.09%	+128.31%	54.63B
INSMED INCORPORATED	-5.60%	-2.15%	+11.16%	+420.46%	25.06B
BIONTECH SE	-1.55%	-4.11%	-20.21%	-17.75%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+0.38%	+2.01%	+40.26%	-8.26%	19.87B
GENMAB A/S	+1.87%	+4.16%	+38.13%	-26.42%	17.55B
PHARMAESSENTIA CORPORATION	-2.72%	-4.04%	+187.08%	+362.09%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.38%	-4.55%	+43.12%	+643.33%	15.75B
EXELIXIS, INC.	-0.81%	+0.92%	+24.92%	+189.61%	14.2B
Average	-1.40%	-10.87%	+48.71%	+196.72%	24.16B
Weighted average by Cap.	-1.64%	-1.64%	+48.18%	+164.13%

	2021	2022
Net sales	-	19.64M 17.22M 15.95M 14.68M 27.76M 1.88B 28.3M 190M 74.57M 923M 73.74M 72.13M 3.19B
Net income	-58.38M -51.2M -47.42M -43.63M -82.53M -5.59B -84.14M -565M -222M -2.74B -219M -214M -9.48B	-29.88M -26.21M -24.27M -22.33M -42.24M -2.86B -43.06M -289M -113M -1.4B -112M -110M -4.85B
Net Debt	-28.08M -24.62M -22.81M -20.98M -39.69M -2.69B -40.46M -272M -107M -1.32B -105M -103M -4.56B	-5.4M -4.73M -4.38M -4.03M -7.63M -517M -7.78M -52.25M -20.49M -254M -20.27M -19.82M -876M